Taxane-induced peripheral neurotoxicity

Toxics

Volumn 3, Issue 2, 2015, Pages 152-169

  Velasco, Roser ^a,b   Bruna, Jordi ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cabazitaxel; Chemotherapy induced peripheral neuropathy; Docetaxel; Nab paclitaxel; Neurotoxicity; Paclitaxel; Peripheral neuropathy; Taxane; Taxane induced peripheral neuropathy

Indexed keywords

EID: 84991329630     PISSN: None     EISSN: 23056304     Source Type: Journal    
DOI: 10.3390/toxics3020152     Document Type: Review

References (112)

1. Rowinsky, E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 1997, 48, 353-374.
2. Mekhail, T.M.; Markman, M. Paclitaxel in cancer therapy. Expert Opin. Pharmacother. 2002, 3, 755-766.
3. Bachegowda, L.S.; Makower, D.F.; Sparano, J.A. Taxanes: Impact on breast cancer therapy. Anticancer Drugs 2014, 25, 512-521.
4. Zhang, D.; Yang, R.; Wang, S.; Dong, Z. Paclitaxel: New uses for an old drug. Drug Des. Dev. Ther. 2014, 8, 279-284.
5. Yared, J.A.; Tkaczuk, K.H. Update on taxane development: New analogs and new formulations. Drug Des. Dev. Ther. 2012, 6, 371-384.
6. Muggia, F.; Kudlowitz, D. Novel taxanes. Anticancer Drugs 2014, 25, 593-598.
7. Zhang, Z.; Mei, L.; Feng, S.S. Paclitaxel drug delivery systems. Expert Opin. Drug Deliv. 2013, 10, 325-340.
8. Bhatnagar, B.; Gilmore, S.; Goloubeva, O.; Pelser, C.; Medeiros, M.; Chumsri, S.; Tkaczuk, K.; Edelman, M.; Bao, T. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: A single-center experience. Springerplus 2014, 3, 366.
9. Speck, R.M.; Sammel, M.D.; Farrar, J.T.; Hennessy, S.; Mao, J.J.; Stineman, M.G.; DeMichele, A. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J. Oncol. Pract. 2013, 9, e234-e240.
10. Ezendam, N.P.; Pijlman, B.; Bhugwandass, C.; Pruijt, J.F.; Mols, F.; Vos, M.C.; Pijnenborg, J.M.; van de Poll-Franse, L.V. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: Results from the population-based PROFILES registry. Gynecol. Oncol. 2014, 135, 510-517.
11. Pike, C.T.; Birnbaum, H.G.; Muehlenbein, C.E.; Pohl, G.M.; Natale, R.B. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother. Res. Pract. 2012, 2012, 913848.
12. Rivera, E.; Cianfrocca, M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother. Pharmacol. 2015, 75, 659-670.
13. Stubblefield, M.D.; Burstein, H.J.; Burton, A.W.; Custodio, C.M.; Deng, G.E.; Ho, M.; Junck, L.; Morris, G.S.; Paice, J.A.; Tummala, S.; et al. NCCN task force report: Management of neuropathy in cancer. J. Natl. Compr. Cancer Netw. 2009, 7 (suppl. 5), S1-S26.
14. Jones, S.E.; Erban, J.; Overmoyer, B.; Budd, G.T.; Hutchins, L.; Lower, E.; Laufman, L.; Sundaram, S.; Urba, W.J.; Pritchard, K.I.; et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 2005, 23, 5542-5551.
15. Eckhoff, L.; Knoop, A.S.; Jensen, M.B.; Ejlertsen, B.; Ewertz, M. Risk of docetaxel-induced peripheral neuropathy among 1725 Danish patients with early stage breast cancer. Breast Cancer Res. Treat. 2013, 142, 109-118.
16. Kudlowitz, D.; Muggia, F. Defining risks of taxane neuropathy: Insights from randomized clinical trials. Clin. Cancer Res. 2013, 19, 4570-4577.
17. Miltenburg, N.C.; Boogerd, W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat. Rev. 2014, 40, 872-882.
18. Argyriou, A.A.; Bruna, J.; Marmiroli, P.; Cavaletti, G. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Crit. Rev. Oncol. Hematol. 2012, 82, 51-77.
19. Schneider, B.P.; Zhao, F.; Wang, M.; Stearns, V.; Martino, S.; Jones, V.; Perez, E.A.; Saphner, T.; Wolff, A.C.; Sledge, G.W.; et al. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J. Clin. Oncol. 2012, 30, 3051-3057.
20. Cavaletti, G.; Frigeni, B.; Lanzani, F.; Piatti, M.; Rota, S.; Briani, C.; Zara, G.; Plasmati, R.; Pastorelli, F.; Caraceni, A.; et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: Comparison with the National Cancer Institute-Common Toxicity Scale. J. Peripher. Nerv. Syst. 2007, 12, 210-215.
21. Park, S.B.; Lin, C.S.; Krishnan, A.V.; Friedlander, M.L.; Lewis, C.R.; Kiernan, M.C. Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve 2011, 43, 367-374.
22. Pace, A.; Nisticò, C.; Cuppone, F.; Bria, E.; Galiè, E.; Graziano, G.; Natoli, G.; Sperduti, I.; Jandolo, B.; Calabretta, F.; et al. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: A schedule or a dose issue? Clin. Breast Cancer 2007, 7, 550-554.
23. Alberti, P.; Rossi, E.; Cornblath, D.R.; Merkies, I.S.; Postma, T.J.; Frigeni, B.; Bruna, J.; Velasco, R.; Argyriou, A.A.; Kalofonos, H.P.; et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: Two sides of the same coin. Ann. Oncol. 2014, 25, 257-264.
24. Gradishar, W.J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23, 7794-7803.
25. Hirsh, V.; Okamoto, I.; Hon, J.K.; Page, R.D.; Orsini, J.; Sakai, H.; Zhang, H.; Renschler, M.F.; Socinski, M.A. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin vs. solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J. Thorac Oncol. 2014, 9, 83-90.
26. Bahl, A.; Oudard, S.; Tombal, B.; Ozgüroglu, M.; Hansen, S.; Kocak, I.; Gravis, G.; Devin, J.; Shen, L.; de Bono, J.S.; et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann. Oncol. 2013, 24, 2402-2408.
27. De Bono, J.S.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J.P.; Kocak, I.; Gravis, G.; Bodrogi, I.; Mackenzie, M.J.; Shen, L.; et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010, 376, 1147-1154.
28. Ahn, H.K.; Jung, M.; Sym, S.J.; Shin, D.B.; Kang, S.M.; Kyung, S.Y.; Park, J.W.; Jeong, S.H.; Cho, E.K. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 2014, 74, 277-282.
29. Lee, J.J.; Swain, S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J. Clin. Oncol. 2006, 24, 1633-1642.
30. Rowinsky, E.K.; Donehower, R.C. Paclitaxel (taxol). N. Engl. J. Med. 1995, 332, 1004-1014.
31. Argyriou, A.A.; Koltzenburg, M.; Polychronopoulos, P.; Papapetropoulos, S.; Kalofonos, H.P. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit. Rev. Oncol. Hematol. 2008, 66, 218-228.
32. Gornstein, E.; Schwarz, T.L. The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology 2014, 76, 175-183.
33. Cavaletti, G.; Tredici, G.; Braga, M.; Tazzari, S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp. Neurol. 1995, 133, 64-72.
34. Cavaletti, G.; Cavalletti, E.; Montaguti, P.; Oggioni, N.; de Negri, O.; Tredici, G. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 1997, 18, 137-145.
35. Peters, C.M.; Jimenez-Andrade, J.M.; Kuskowski, M.A.; Ghilardi, J.R.; Mantyh, P.W. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res. 2007, 1168, 46-59.
36. Shemesh, O.A.; Spira, M.E. Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: Implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta Neuropathol. 2010, 119, 235-248.
37. Scuteri, A.; Nicolini, G.; Miloso, M.; Bossi, M.; Cavaletti, G.; Windebank, A.J.; Tredici, G. Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Res. 2006, 26, 1065-1070.
38. Zhang, H.; Dougherty, P.M. Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. Anesthesiology 2014, 120, 1463-1475.
39. Gregg, R.W.; Molepo, J.M.; Monpetit, V.J.; Mikael, N.Z.; Redmond, D.; Gadia, M.; Stewart, D.J. Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J. Clin. Oncol. 1992, 10, 795-803.
40. Flatters, S.J.; Bennett, G.J. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction. Pain 2006, 122, 245-257.
41. Xiao, W.H.; Zheng, H.; Zheng, F.Y.; Nuydens, R.; Meert, T.F.; Bennett, G.J. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neuroscience 2011, 199, 461-469.
42. Bennett, G.J.; Doyle, T.; Salvemini, D. Mitotoxicity in distal symmetrical sensory peripheral neuropathies. Nat. Rev. Neurol. 2014, 10, 326-336.
43. Xiao, W.H.; Bennett, G.J. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain 2012, 153, 704-709.
44. Dougherty, P.M.; Cata, J.P.; Cordella, J.V.; Burton, A.; Weng, H.R. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004, 109, 132-142.
45. Loprinzi, C.L.; Maddocks-Christianson, K.; Wolf, S.L.; Rao, R.D.; Dyck, P.J.; Mantyh, P.; Dyck, P.J. The Paclitaxel acute pain syndrome: Sensitization of nociceptors as the putative mechanism. Cancer J. 2007, 13, 399-403.
46. Loprinzi, C.L.; Reeves, B.N.; Dakhil, S.R.; Sloan, J.A.; Wolf, S.L.; Burger, K.N.; Kamal, A.; Le-Lindqwister, N.A.; Soori, G.S.; Jaslowski, A.J.; et al. Natural history of paclitaxel-associated acute pain syndrome: Prospective cohort study NCCTG N08C1. J. Clin. Oncol. 2011, 29, 1472-1478.
47. Wang, X.M.; Lehky, T.J.; Brell, J.M.; Dorsey, S.G. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012, 59, 3-9.
48. Sahenk, Z.; Barohn, R.; New, P.; Mendell, J.R. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch. Neurol. 1994, 51, 726-729.
49. Wiernik, P.H.; Schwartz, E.L.; Strauman, J.J.; Dutcher, J.P.; Lipton, R.B.; Paietta, E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987, 47, 2486-2493.
50. Van den Bent, M.J.; van Raaij-van den Aarssen, V.J.; Verweij, J.; Doorn, P.A.; Sillevis Smitt, P.A. Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve 1997, 20, 750-752.
51. Fazio, R.; Quattrini, A.; Bolognesi, A.; Bordogna, G.; Villa, E.; Previtali, S.; Canal, N.; Nemni, R. Docetaxel neuropathy: A distal axonopathy. Acta Neuropathol. 1999, 98, 651-653.
52. Mantyh, P.W. Cancer pain and its impact on diagnosis, survival and quality of life. Nat. Rev. Neurosci. 2006, 7, 797-809.
53. Boyette-Davis, J.; Xin, W.; Zhang, H.; Dougherty, P.M. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain 2011, 152, 308-313.
54. Ko, M.H.; Hu, M.E.; Hsieh, Y.L.; Lan, C.T.; Tseng, T.J. Peptidergic intraepidermal nerve fibers in the skin contribute to the neuropathic pain in paclitaxel-induced peripheral neuropathy. Neuropeptides 2014, 48, 109-117.
55. Koskinen, M.J.; Kautio, A.L.; Haanpää, M.L.; Haapasalo, H.K.; Kellokumpu-Lehtinen, P.L.; Saarto, T.; Hietaharju, A.J. Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy. Anticancer Res. 2011, 31, 4413-4416.
56. Krøigård, T.; Schrøder, H.D.; Qvortrup, C.; Eckhoff, L.; Pfeiffer, P.; Gaist, D.; Sindrup, S.H. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur. J. Neurol. 2014, 21, 623-629.
57. Boyette-Davis, J.A.; Cata, J.P.; Driver, L.C.; Novy, D.M.; Bruel, B.M.; Mooring, D.L.; Wendelschafer-Crabb, G.; Kennedy, W.R.; Dougherty, P.M. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. Cancer Chemother. Pharmacol. 2013, 71, 619-626.
58. Rowinsky, E.K.; Eisenhauer, E.A.; Chaudhry, V.; Arbuck, S.G.; Donehower, R.C. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 1993, 20, 1-15.
59. Saibil, S.; Fitzgerald, B.; Freedman, O.C.; Amir, E.; Napolskikh, J.; Salvo, N.; Dranitsaris, G.; Clemons, M. Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: A retrospective, outcomes-based survey. Curr. Oncol. 2010, 17, 42-47.
60. Tofthagen, C.; McAllister, R.D.; Visovsky, C. Peripheral neuropathy caused by paclitaxel and docetaxel: An evaluation and comparison of symptoms. J. Adv. Pract. Oncol. 2013, 4, 204-215.
61. Moulder, S.L.; Holmes, F.A.; Tolcher, A.W.; Thall, P.; Broglio, K.; Valero, V.; Buzdar, A.U.; Arbuck, S.G.; Seidman, A.; Hortobagyi, G.N. A randomized phase 2 trial comparing 3-h vs. 96-h infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 2010, 116, 814-821.
62. Hilkens, P.H.; Verweij, J.; Vecht, C.J.; Stoter, G.; van den Bent, M.J. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann. Oncol. 1997, 8, 187-190.
63. Openshaw, H.; Beamon, K.; Synold, T.W.; Longmate, J.; Slatkin, N.E.; Doroshow, J.H.; Forman, S.; Margolin, K.; Morgan, R.; Shibata, S.; et al. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: Lack of neuroprotective effect of amifostine. Clin. Cancer Res. 2004, 10, 461-467.
64. Freilich, R.J.; Balmaceda, C.; Seidman, A.D.; Rubin, M.; DeAngelis, L.M. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996, 47, 115-118.
65. Chaudhry, V.; Rowinsky, E.K.; Sartorius, S.E.; Donehower, R.C.; Cornblath, D.R. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann. Neurol. 1994, 35, 304-311.
66. Osmani, K.; Vignes, S.; Aissi, M.; Wade, F.; Milani, P.; Lévy, B.I.; Kubis, N. Taxane-induced peripheral neuropathy has good long-term prognosis: A 1-to 13-year evaluation. J. Neurol. 2012, 259, 1936-1943.
67. Jerian, S.M.; Sarosy, G.A.; Link, C.J.; Fingert, H.J.; Reed, E.; Kohn, E.C. Incapacitating autonomic neuropathy precipitated by taxol. Gynecol. Oncol. 1993, 51, 277-280.
68. Ekholm, E.M.; Salminen, E.K.; Huikuri, H.V.; Jalonen, J.; Antila, K.J.; Salmi, T.A.; Rantanen, V.T. Impairment of heart rate variability during paclitaxel therapy. Cancer 2000, 88, 2149-2153.
69. Ekholm, E.; Rantanen, V.; Antila, K.; Salminen, E. Paclitaxel changes sympathetic control of blood pressure. Eur. J. Cancer 1997, 33, 1419-1424.
70. Barutcu, I.; Sezgin, A.T.; Gullu, H.; Esen, A.M.; Ozdemir, R. Effect of paclitaxel administration on P wave duration and dispersion. Clin. Auton. Res. 2004, 14, 34-38.
71. Ekholm, E.; Rantanen, V.; Syvänen, K.; Jalonen, J.; Antila, K.; Salminen, E. Docetaxel does not impair cardiac autonomic function in breast cancer patients previously treated with anthracyclines. Anticancer Drugs 2002, 13, 425-429.
72. Tanabe, Y.; Hashimoto, K.; Shimizu, C.; Hirakawa, A.; Harano, K.; Yunokawa, M.; Yonemori, K.; Katsumata, N.; Tamura, K.; Ando, M.; et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int. J. Clin. Oncol. 2013, 18, 132-138.
73. Shimozuma, K.; Ohashi, Y.; Takeuchi, A.; Aranishi, T.;Morita, S.; Kuroi, K.; Ohsumi, S.;Makino, H.; Katsumata, N.; Kuranami, M.; et al. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer 2012, 20, 3355-3364.
74. Hershman, D.L.; Weimer, L.H.; Wang, A.; Kranwinkel, G.; Brafman, L.; Fuentes, D.; Awad, D.; Crew, K.D. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res. Treat. 2011, 125, 767-774.
75. Pignata, S.; de Placido, S.; Biamonte, R.; Scambia, G.; di Vagno, G.; Colucci, G.; Febbraro, A.; Marinaccio, M.; Lombardi, A.V.; Manzione, L.; et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006, 6, 5.
76. Seidman, A.D.; Berry, D.; Cirrincione, C.; Harris, L.; Muss, H.; Marcom, P.K.; Gipson, G.; Burstein, H.; Lake, D.; Shapiro, C.L.; et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J. Clin. Oncol. 2008, 26, 1642-1649.
77. Sparano, J.A.; Wang, M.; Martino, S.; Jones, V.; Perez, E.A.; Saphner, T.; Wolff, A.C.; Sledge, G.W.; Wood, W.C.; Davidson, N.E. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 2008, 358, 1663-1671.
78. Huang, T.; Campbell, T.C. Comparison of weekly vs. every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis. Cancer Treat. Rev. 2012, 38, 613-617.
79. Mauri, D.; Kamposioras, K.; Tsali, L.; Bristianou, M.; Valachis, A.; Karathanasi, I.; Georgiou, C.; Polyzos, N.P. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treat. Rev. 2010, 36, 69-74.
80. Di Maio, M.; Perrone, F.; Chiodini, P.; Gallo, C.; Camps, C.; Schuette, W.; Quoix, E.; Tsai, C.M.; Gridelli, C. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 2007, 25, 1377-1382.
81. Rivera, E.; Mejia, J.A.; Arun, B.K.; Adinin, R.B.; Walters, R.S.; Brewster, A.; Broglio, K.R.; Yin, G.; Esmaeli, B.; Hortobagyi, G.N.; et al. Phase 3 study comparing the use of docetaxel on an every-3-week vs. weekly schedule in the treatment of metastatic breast cancer. Cancer 2008, 112, 1455-1461.
82. Smith, R.E.; Brown, A.M.; Mamounas, E.P.; Anderson, S.J.; Lembersky, B.C.; Atkins, J.H.; Shibata, H.R.; Baez, L.; DeFusco, P.A.; Davila, E.; et al. Randomized trial of 3-h vs. 24-h infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J. Clin. Oncol. 1999, 17, 3403-3411.
83. Mielke, S.; Mross, K.; Gerds, T.A.; Schmidt, A.; Wäsch, R.; Berger, D.P.; Lange, W.; Behringer, D. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 vs. 3 h. Anticancer Drugs 2003, 14, 785-792.
84. De Jongh, F.E.; van Veen, R.N.; Veltman, S.J.; de Wit, R.; van der Burg, M.E.; van den Bent, M.J.; Planting, A.S.; Graveland, W.J.; Stoter, G.; Verweij, J. Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients. Br. J. Cancer 2003, 88, 1199-1206.
85. Miles, D.W.; Chan, A.; Dirix, L.Y.; Cortés, J.; Pivot, X.; Tomczak, P.; Delozier, T.; Sohn, J.H.; Provencher, L.; Puglisi, F.; et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 2010, 28, 3239-4327.
86. Smith, I.E.; Pierga, J.Y.; Biganzoli, L.; Cortés-Funes, H.; Thomssen, C.; Pivot, X.; Fabi, A.; Xu, B.; Stroyakovskiy, D.; Franke, F.A.; et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: Safety and efficacy in an open-label study in 2251 patients. Ann. Oncol. 2011, 22, 595-602.
87. Robert, N.J.; Diéras, V.; Glaspy, J.; Brufsky, A.M.; Bondarenko, I.; Lipatov, O.N.; Perez, E.A.; Yardley, D.A.; Chan, S.Y.; Zhou, X.; et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 2011, 29, 1252-1260.
88. Verheyen, A.; Peeraer, E.; Nuydens, R.; Dhondt, J.; Poesen, K.; Pintelon, I.; Daniels, A.; Timmermans, J.P.; Meert, T.; Carmeliet, P.; et al. Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy. Brain 2012, 135, 2629-2641.
89. Akerley, W.; Herndon, J.E.; Egorin, M.J.; Lyss, A.P.; Kindler, H.L.; Savarese, D.M.; Sherman, C.A.; Rosen, D.M.; Hollis, D.; Ratain, M.J.; et al. Weekly, high-dose paclitaxel in advanced lung carcinoma: A phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 2003, 97, 2480-2486.
90. Chen, Y.M.; Perng, R.P.; Shih, J.F.; Tsai, C.M.;Whang-Peng, J. Chemotherapy for non-small cell lung cancer in elderly patients. Chest 2005, 128, 132-139.
91. Argyriou, A.A.; Polychronopoulos, P.; Koutras, A.; Iconomou, G.; Gourzis, P.; Assimakopoulos, K.; Kalofonos, H.P.; Chroni, E. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 2006, 14, 223-229.
92. Nurgalieva, Z.; Xia, R.; Liu, C.C.; Burau, K.; Hardy, D.; Du, X.L. Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am. J. Ther. 2010, 17, 148-158.
93. Hertz, D.L.; Roy, S.; Motsinger-Reif, A.A.; Drobish, A.; Clark, L.S.; McLeod, H.L.; Carey, L.A.; Dees, E.C. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann. Oncol. 2013, 24, 1472-1478.
94. Weimer, L.H.; Podwall, D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J. Neurol. Sci. 2006, 242, 47-54.
95. Hertz, D.L.; Motsinger-Reif, A.A.; Drobish, A.; Winham, S.J.; McLeod, H.L.; Carey, L.A.; Dees, E.C. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res. Treat. 2012, 134, 401-410.
96. Bergmann, T.K.; Gréen, H.; Brasch-Andersen, C.; Mirza, M.R.; Herrstedt, J.; Hølund, B.; du Bois, A.; Damkier, P.; Vach, W.; Brosen, K.; et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur. J. Clin. Pharmacol. 2011, 67, 693-700.
97. Sissung, T.M.; Mross, K.; Steinberg, S.M.; Behringer, D.; Figg, W.D.; Sparreboom, A.; Mielke, S. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur. J. Cancer 2006, 42, 2893-2896.
98. Chhibber, A.; Mefford, J.; Stahl, E.A.; Pendergrass, S.A.; Baldwin, R.M.; Owzar, K.; Li, M.; Winer, E.P.; Hudis, C.A.; Zembutsu, H.; et al. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Pharmacogenomics J. 2014, 14, 336-342.
99. Beutler, A.S.; Kulkarni, A.A.; Kanwar, R.; Klein, C.J.; Therneau, T.M.; Qin, R.; Banck, M.S.; Boora, G.K.; Ruddy, K.J.; Wu, Y.; et al. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann. Neurol. 2014, 76, 727-737.
100. Gréen, H.; Söderkvist, P.; Rosenberg, P.; Mirghani, R.A.; Rymark, P.; Lundqvist, E.A.; Peterson, C. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin. Pharmacol. Toxicol. 2009, 104, 130-137.
101. Baldwin, R.M.; Owzar, K.; Zembutsu, H.; Chhibber, A.; Kubo, M.; Jiang, C.; Watson, D.; Eclov, R.J.; Mefford, J.; McLeod, H.L.; et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin. Cancer Res. 2012, 18, 5099-5109.
102. Abraham, J.E.; Guo, Q.; Dorling, L.; Tyrer, J.; Ingle, S.; Hardy, R.; Vallier, A.L.; Hiller, L.; Burns, R.; Jones, L.; et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin. Cancer Res. 2014, 20, 2466-2475.
103. Apellániz-Ruiz, M.; Lee, M.Y.; Sánchez-Barroso, L.; Gutiérrez-Gutiérrez, G.; Calvo, I.; García-Estévez, L.; Sereno, M.; García-Donás, J.; Castelo, B.; Guerra, E.; et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clin. Cancer Res. 2015, 21, 322-328.
104. Hershman, D.L.; Lacchetti, C.; Dworkin, R.H.; Lavoie Smith, E.M.; Bleeker, J.; Cavaletti, G.; Chauhan, C.; Gavin, P.; Lavino, A.; Lustberg, M.B.; et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2014, 32, 1941-1967.
105. Pronk, L.C.; Hilkens, P.H.; van den Bent, M.J.; van Putten, W.L.; Stoter, G.; Verweij, J. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anticancer Drugs 1998, 9, 759-764.
106. Leal, A.D.; Qin, R.; Atherton, P.J.; Haluska, P.; Behrens, R.J.; Tiber, C.H.; Watanaboonyakhet, P.; Weiss, M.; Adams, P.T.; Dockter, T.J.; et al. Alliance for Clinical Trials in Oncology North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled study. Cancer 2014, 120, 1890-1897.
107. Argyriou, A.A.; Chroni, E.; Koutras, A.; Iconomou, G.; Papapetropoulos, S.; Polychronopoulos, P.; Kalofonos, H.P. Preventing paclitaxel-induced peripheral neuropathy: A phase II trial of vitamin E supplementation. J. Pain Symptom Manag. 2006, 32, 237-244.
108. Kottschade, L.A.; Sloan, J.A.; Mazurczak, M.A.; Johnson, D.B.; Murphy, B.P.; Rowland, K.M.; Smith, D.A.; Berg, A.R.; Stella, P.J.; Loprinzi, C.L. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: Results of a randomized phase III clinical trial. Support Care Cancer 2011, 19, 1769-1777.
109. Pachman, D.R.; Watsonm, J.C.; Lustberg, M.B.; Wagner-Johnston, N.D.; Chan, A.; Broadfield, L.; Cheung, Y.T.; Steer, C.; Storey, D.J.; Chandwani, K.D.; et al. Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer 2014, 22, 2281-2295.
110. Smith, E.M.; Pang, H.; Cirrincione, C.; Fleishman, S.; Paskett, E.D.; Ahles, T.; Bressler, L.R.; Fadul, C.E.; Knox, C.; Le-Lindqwister, N.; et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial. JAMA 2013, 309, 1359-1367.
111. Velasco, R; Bruna, J.; Briani, C.; Argyriou, A.A.; Cavaletti, G.; Alberti, P.; Frigeni, B.; Cacciavillani, M.; Lonardi, S.; Cortinovis, D.; et al. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J. Neurol. Neurosurg. Psychiatry 2014, 85, 392-398.
112. Velasco, R.; Petit, J.; Clapés, V.; Verdú, E.; Navarro, X.; Bruna, J. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J. Peripher. Nerv. Syst. 2010, 15, 17-25.